CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: The Company develops, manufactures, and markets consumer and specialty products, primarily under the ARM & HAMMER brand. Key segments include Consumer Products (Deodorizing/Cleaning, Laundry, Personal Care) and Specialty Products (Sodium bicarbonate, animal nutrition). The Company also holds a 50% interest in Armkel LLC, a joint venture with Kelso & Company, which markets Trojan condoms, Nair depilatories, and First Response pregnancy tests.

Key Financial Metrics (2003)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 0.9% to $1,056.9 million. Growth was driven by the fourth-quarter acquisition of Unilever's oral care brands (Mentadent, Pepsodent, Aim, Close-Up) and favorable foreign exchange, partially offset by a change in revenue recognition policy (FOB Shipping to FOB Destination) which reduced reported sales by approximately $6.3 million.
• Profitability: Net income rose 21.4% to $81.0 million. Operating income increased 7.1% to $111.9 million. Gross margin improved to 30.1% due to efficiencies in consumer products, though specialty product margins were pressured by higher ingredient costs.
• Acquisitions: The Company acquired oral care assets from Unilever for approximately $104 million in cash plus performance-based payments. It also paid a $3.4 million earn-out related to the 2002 Biovance Technologies acquisition.
• Debt Refinancing: The Company refinanced $100 million of term loans via the issuance of 5.25% convertible senior debentures due in 2033. It also entered a receivables purchase agreement to refinance $60 million of its credit facility.

Guidance, Outlook, and Risks

• Financial Objectives: Management targets average annual earnings per share growth of 12.5% to 15% for the 2003-2005 period. The goal is to improve combined gross margins by at least 1% annually, assuming stable commodity prices.
• Outlook: The Company expects high single-digit sales growth for 2004, including acquired brands. It plans to stabilize declining sales in former Unilever brands through revitalization efforts and integration.
• Key Risks:
  • Competition: Intense competition in mature markets (laundry, personal care) from larger rivals (P&G, Unilever) may force price concessions or increased marketing spend.
  • Customer Concentration: Wal-Mart accounted for 17% of net sales in 2003. Loss of this customer would significantly impact results.
  • Raw Materials: Increases in costs for surfactants, paper, and energy could erode margins if not passed to consumers.
  • Regulatory/Litigation: Potential FDA restrictions on N-9 spermicide in Trojan condoms; pending appraisal litigation regarding the Carter-Wallace merger (potential liability up to $2.1 million for the Company).

Investor Verification Checklist

• Oral Care Integration: Verify the progress of integrating Unilever's oral care brands and the success of revitalization strategies for declining brands (Pepsodent, Aim).
• Armkel Call Option: Monitor the Company's decision regarding the option to acquire the remaining 50% interest in Armkel LLC, exercisable between late 2004 and late 2006.
• Margin Sustainability: Assess whether the 30.1% gross margin is sustainable given rising raw material costs and competitive pricing pressure.
• Convertible Debt: Review the terms of the $100 million convertible debentures, specifically the conversion price ($46.50) and potential dilution if the stock price exceeds the 20% premium threshold.
• Legal Contingencies: Track the outcome of the Carter-Wallace shareholder appraisal litigation and any FDA guidance regarding N-9 in condoms.